Low-grade Gliomas

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2014 Mar 26

PMID 24664484

Citations 115

Authors

Deborah A Forst

Brian V Nahed

Jay S Loeffler

Tracy T Batchelor

Affiliations

Soon will be listed here.

Abstract

Low-grade gliomas (LGGs) are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade gliomas. Treatment options include observation, surgery, radiation, chemotherapy, or a combined approach, and management is individualized based on tumor location, histology, molecular profile, and patient characteristics. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks. We review in this article current management strategies for LGG, including surgery, radiotherapy, and chemotherapy. In addition, the importance of profiling the genetic and molecular properties of LGGs in the development of targeted anticancer therapies is also reviewed. Finally, given the prevalence of these tumors in otherwise healthy young patients, the impact of treatment on neurocognitive function and quality of life is also evaluated.

Citing Articles

Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis.

Falcao L, Araujo Cerqueira G, Goncalves J, de Andrade J, de Azevedo Figueiredo Trocoli C, Souza Medrado-Nunes G Neurosurg Rev. 2025; 48(1):281.

PMID: 40032671 DOI: 10.1007/s10143-025-03428-x.

Development and validation of a robust MRI-based nomogram incorporating radiomics and deep features for preoperative glioma grading: a multi-center study.

Bijari S, Rezaeijo S, Sayfollahi S, Rahimnezhad A, Heydarheydari S Quant Imaging Med Surg. 2025; 15(2):1125-1138.

PMID: 39995745 PMC: 11847178. DOI: 10.21037/qims-24-1543.

Cinnamaldehyde impacts key cellular signaling pathways for induction of programmed cell death in high-grade and low-grade human glioma cells.

Kim Y, Patil K, Pai S BMC Res Notes. 2025; 18(1):23.

PMID: 39833890 PMC: 11744947. DOI: 10.1186/s13104-025-07092-8.

Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.

Shirvalilou S, Khoei S, Afzalipour R, Ghaznavi H, Shirvaliloo M, Derakhti Z Med Oncol. 2024; 41(12):303.

PMID: 39470962 DOI: 10.1007/s12032-024-02546-8.

Application of a risk score model based on glycosylation-related genes in the prognosis and treatment of patients with low-grade glioma.

Zou B, Li M, Zhang J, Gao Y, Huo X, Li J Front Immunol. 2024; 15:1467858.

PMID: 39445005 PMC: 11496118. DOI: 10.3389/fimmu.2024.1467858.

References

Douw L, Klein M, Fagel S, van den Heuvel J, Taphoorn M, Aaronson N . Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009; 8(9):810-8. DOI: 10.1016/S1474-4422(09)70204-2. View

Pouratian N, Schiff D . Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010; 10(3):224-31. PMC: 2857752. DOI: 10.1007/s11910-010-0105-7. View

Khasraw M, Lassman A . Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma. Nat Rev Neurol. 2009; 5(12):646-7. DOI: 10.1038/nrneurol.2009.194. View

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

Youland R, Brown P, Giannini C, Parney I, Uhm J, Laack N . Adult low-grade glioma: 19-year experience at a single institution. Am J Clin Oncol. 2012; 36(6):612-9. PMC: 4361933. DOI: 10.1097/COC.0b013e31825d580a. View

Smith J, Perry A, Borell T, Lee H, OFallon J, Hosek S . Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18(3):636-45. DOI: 10.1200/JCO.2000.18.3.636. View

Sanai N, Berger M . Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008; 62(4):753-64. DOI: 10.1227/01.neu.0000318159.21731.cf. View

Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E . IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol. 2013; 15(4):469-79. PMC: 3607260. DOI: 10.1093/neuonc/nos317. View

Pirzkall A, Nelson S, McKnight T, Takahashi M, Li X, Graves E . Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys. 2002; 53(5):1254-64. DOI: 10.1016/s0360-3016(02)02869-9. View

10.

Afra D, Osztie E, Sipos L, Vitanovics D . Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg. 1999; 13(3):299-305. DOI: 10.1080/02688699943727. View

11.

Sorensen A, Batchelor T, Wen P, Zhang W, Jain R . Response criteria for glioma. Nat Clin Pract Oncol. 2008; 5(11):634-44. PMC: 4795821. DOI: 10.1038/ncponc1204. View

12.

Krueger D, Care M, Holland K, Agricola K, Tudor C, Mangeshkar P . Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 363(19):1801-11. DOI: 10.1056/NEJMoa1001671. View

13.

Baumert B, Stupp R . Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. Ann Oncol. 2008; 19 Suppl 7:vii217-22. DOI: 10.1093/annonc/mdn434. View

14.

Claus E, Horlacher A, Hsu L, Schwartz R, Dello-Iacono D, Talos F . Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005; 103(6):1227-33. DOI: 10.1002/cncr.20867. View

15.

Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C . Molecular markers in low-grade gliomas: predictive or prognostic?. Clin Cancer Res. 2011; 17(13):4588-99. DOI: 10.1158/1078-0432.CCR-10-3194. View

16.

Peraud A, Ansari H, Bise K, Reulen H . Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir (Wien). 1999; 140(12):1213-22. DOI: 10.1007/s007010050241. View

17.

Pouratian N, Asthagiri A, Jagannathan J, Shaffrey M, Schiff D . Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol. 2007; 3(11):628-39. DOI: 10.1038/ncpneuro0634. View

18.

Kiebert G, Curran D, Aaronson N, Bolla M, Menten J, Rutten E . Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1999; 34(12):1902-9. DOI: 10.1016/s0959-8049(98)00268-8. View

19.

van den Bent M, Afra D, De Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K . Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366(9490):985-90. DOI: 10.1016/S0140-6736(05)67070-5. View

20.

Chang E, Potts M, Keles G, Lamborn K, Chang S, Barbaro N . Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008; 108(2):227-35. DOI: 10.3171/JNS/2008/108/2/0227. View